ProMIS Neurosciences Validates Plasma pTau as Early Predictor for Alzheimer's Drug Development
核心洞察
ProMIS Neurosciences published peer-reviewed research demonstrating that plasma phosphorylated tau (pTau) biomarkers can predict clinical outcomes in Alzheimer's disease trials with strong correlation (≈0.78).
The analysis showed plasma pTau changes at 6 months were 2.6 times larger than clinical effects at 12 months, enabling smaller trials with approximately 100 participants for proof-of-concept studies.
The findings validate ProMIS's biomarker-driven approach in their ongoing PRECISE-AD Phase 1b trial of PMN310, with interim results expected in Q2 2026.
ProMIS Neurosciences has published new research validating the use of plasma phosphorylated tau (pTau) biomarkers as early predictors of clinical benefit in Alzheimer's disease trials, providing scientific support for the company's ongoing Phase 1b PRECISE-AD study of its lead drug candidate PMN310.
The peer-reviewed analysis, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, demonstrates that plasma pTau measurements can serve as meaningful primary endpoints in early-stage Alzheimer's trials, potentially revolutionizing drug development efficiency in the field.
Strong Predictive Correlation Demonstrated
The cross-trial analysis conducted by Pentara Corporation (搜索) in collaboration with ProMIS scientists examined summary data from several large monoclonal antibody trials in early Alzheimer's disease. The research revealed a strong predictive relationship between early biomarker changes and later clinical outcomes.
"Group level treatment effects on plasma pTau at 6 months were strongly correlated with treatment effects on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 12 months (correlation ≈ 0.78; statistically significant)," according to the publication.
The analysis showed that the effect size on plasma pTau was approximately 2.6 times larger than the effect size on CDR-SB, indicating that biomarker changes can be detected earlier and more robustly than clinical changes. This amplified signal suggests that plasma pTau offers a more sensitive readout of drug effects compared to traditional clinical endpoints.
Implications for Trial Design and Efficiency
The research findings suggest significant potential for improving clinical trial efficiency in Alzheimer's drug development. Simulations indicate that well-powered proof-of-concept trials using plasma pTau as a primary endpoint may require as few as approximately 100 participants for drugs with effect sizes similar to leading monoclonal antibodies.
"By combining data across several large, well-characterized AD trials, we were able to quantify how strongly early plasma pTau changes predicted later clinical outcomes," said Suzanne Hendrix, Ph.D., CEO of Pentara Corporation (搜索) and co-author of the paper. "The magnitude of this relationship, and the fact that the biomarker signal is easier to detect than the clinical signal, make plasma pTau a highly attractive primary endpoint for early proof-of-concept studies."
Validation for PRECISE-AD Trial Strategy
The published analysis directly supports key elements of ProMIS's PRECISE-AD trial design. The ongoing Phase 1b study incorporates plasma pTau, including pTau217 (搜索), as a central biomarker endpoint at 6 and 12 months, consistent with the timing and methodology highlighted in the publication.
"This publication provides important validation of the strategy we have adopted at ProMIS which is to use highly sensitive plasma pTau biomarkers as a central pillar of our ongoing Phase 1b AD clinical trial," said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
The PRECISE-AD trial is evaluating PMN310 in 128 patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease. The randomized, double-blind, placebo-controlled study is testing multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310.
PMN310's Unique Mechanism and Fast Track Status
PMN310 represents a novel approach to Alzheimer's treatment as a humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers while avoiding plaque binding. This selective targeting strategy aims to potentially reduce or eliminate amyloid-related imaging abnormalities (ARIA), a significant safety concern with other amyloid-directed therapies.
The drug candidate received Fast Track designation from the U.S. Food and Drug Administration in July 2025, recognizing its potential to address an unmet medical need in Alzheimer's treatment.
"For PMN310, which is designed to selectively target the toxic amyloid-beta oligomers that trigger tau phosphorylation, we believe plasma pTau offers a sensitive, biologically aligned readout of drug effect that can inform both dose selection and future Phase 3 planning," said Larry D. Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS and co-author of the paper.
Timeline and Future Milestones
ProMIS remains on track to assess blinded 6-month biomarker data, including plasma pTau217 (搜索), from the PRECISE-AD trial in Q2 2026. The company expects this interim analysis to provide an early indication of PMN310's potential to modify disease biology. Final topline data from the study is anticipated in Q4 2026.
The PRECISE-AD study is powered to provide 95% confidence for detection of ARIA and has been designed with sufficient sample size to provide meaningful insights into PMN310's effects on biomarkers and clinical outcomes. As the first study to examine the effects of a monoclonal antibody directed solely against toxic amyloid-beta oligomers, PRECISE-AD represents a significant milestone in Alzheimer's drug development.